Adaptive Biotechnologies COO Julie Rubinstein Divests $826,000 in Equity

Julie Rubinstein, President and COO of Adaptive Biotechnologies Corporation (NASDAQ: ADPT), reported the sale of 57,180 shares of common stock between April 14 and April 16, 2026. According to SEC Form 4 filings, the transactions were executed at a weighted average price of approximately $14.45 per share, resulting in a total transaction value of roughly $826,000. The shares sold were acquired through the exercise of options immediately prior to the sale. This divestment represents approximately 12.29% of Rubinstein's direct holdings at the time. Despite the activity, she remains heavily invested in the company, maintaining 408,160 shares and 148,770 stock options as of April 16. Adaptive Biotechnologies, a Seattle-based commercial-stage biotechnology firm with over 600 employees, continues to leverage its immune medicine platform through strategic collaborations with Microsoft and Genentech. The company's focus remains on developing diagnostics and therapeutics for oncology, autoimmune, and infectious disease markets. Financial indicators for the company's core business remain positive. Revenue from minimal residual disease (MRD) cancer monitoring services increased by 46% last year, supported by expanded Medicare coverage for the clonoSEQ test used in monitoring mantle cell lymphoma patients. Market analysts generally view such insider sales linked to option exercises as routine financial management rather than a lack of confidence in the firm's long-term trajectory.